UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1233-1243

2019

Volltextzugriff (PDF)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

JTO clinical and research reports, 2024-09, Vol.5 (9), p.100700, Article 100700

2024

Volltextzugriff (PDF)

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-12, Vol.138, p.79-87

2019

Volltextzugriff (PDF)

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Volltextzugriff (PDF)

Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

Clinical cancer research, 2017-07, Vol.23 (14), p.3489-3498

2017

Volltextzugriff (PDF)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Oncotarget, 2021-02, Vol.12 (4), p.316-332

2021

Volltextzugriff (PDF)

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Clinical lung cancer, 2021-09, Vol.22 (5), p.473-477

2021

Volltextzugriff (PDF)

Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells

Cancer biology & therapy, 2020-09, Vol.21 (9), p.863-870

2020

Volltextzugriff (PDF)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget, 2018-04, Vol.9 (31), p.22137-22146

2018

Volltextzugriff (PDF)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

Cancer treatment and research communications, 2024, Vol.41, p.100842, Article 100842

2024

Volltextzugriff (PDF)

Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on Bioavailability

Journal of pharmaceutical sciences, 2024-07

2024

Volltextzugriff (PDF)

Opportunities and challenges in using real-world data for health care

The Journal of clinical investigation, 2020-02, Vol.130 (2), p.565-574

2020

Volltextzugriff (PDF)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)

Journal of hematology and oncology, 2020-10, Vol.13 (1), p.143-143, Article 143

2020

Volltextzugriff (PDF)

Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma

Internal Medicine, 2020, pp.4076-19

2020

Volltextzugriff (PDF)

VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma

The Journal of the Japanese Association for Chest Surgery, 2021/05/15, Vol.35(4), pp.297-302

2021

Volltextzugriff (PDF)

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.2009-2018

2019

Volltextzugriff (PDF)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Annals of oncology, 2018-06, Vol.29 (6), p.1409-1416

2018

Volltextzugriff (PDF)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Internal Medicine, 2022, pp.7472-21

2022

Volltextzugriff (PDF)

Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib

European journal of medicinal chemistry, 2021-05, Vol.217, p.113335, Article 113335

2021

Volltextzugriff (PDF)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Annals of oncology, 2018-11, Vol.29 (11), p.2214-2222

2018

Volltextzugriff (PDF)

Treatment of brain metastases in ALK-positive non-small cell lung cancer

Critical reviews in oncology/hematology, 2021-09, Vol.165, p.103400-103400, Article 103400

2021

Volltextzugriff (PDF)

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review

Frontiers in oncology, 2024-08, Vol.14

2024

Volltextzugriff (PDF)

Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer

Journal of clinical and translational endocrinology case reports, 2022-06, Vol.24, p.100113, Article 100113

2022

Volltextzugriff (PDF)

Alectinib induced vitiligo with rapid re-pigmentation

European journal of cancer (1990), 2024-03, Vol.200, p.113582-113582, Article 113582

2024

Volltextzugriff (PDF)

1 – 25 von 425

Suche als RSS-Feed

Aktive Filter

ThemaLung Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(330)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Alectinib
(402)
Science & Technology
(273)
Life Sciences & Biomedicine
(268)
Oncology
(186)
Humans
(142)
Crizotinib
(135)
Lung Neoplasms - Drug Therapy
(93)
Non-Small Cell Lung Cancer
(87)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(85)
Ceritinib
(85)
Anaplastic Lymphoma Kinase
(80)
Brigatinib
(63)
Protein Kinase Inhibitors - Therapeutic Use
(62)
Alk
(61)
Respiratory System
(59)
Nsclc
(58)
Lung Neoplasms - Pathology
(56)
Lorlatinib
(54)
Carbazoles - Therapeutic Use
(53)
Lung Neoplasms - Genetics
(53)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer

Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on Bioavailability

Opportunities and challenges in using real-world data for health care

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)

Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma

VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Treatment of brain metastases in ALK-positive non-small cell lung cancer

Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review

Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer

Alectinib induced vitiligo with rapid re-pigmentation

Aktive Filter

Suchergebnisse filtern